Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Ovarian Neoplasms 4Carcinoma, Ovarian Epithelial 3Platinum-Sensitive Ovarian Cancer in First Relapse 1Pituitary Neoplasms 1Peritoneal Neoplasms 1Neoplasms 1Fallopian Tube Neoplasms 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 8Pemetrexed 8capmatinib 7Carboplatin 7ceritinib 5Cisplatin 5Bevacizumab 4Docetaxel 3trametinib 2motexafin gadolinium 2aldesleukin 2Vinorelbine 2Paclitaxel 2Interleukin-2 2Gefitinib 2BID protein, human 2technetium 99m etarfolatide 1spartalizumab 1sintilimab 1satraplatin 1ribociclib 1picropodophyllin 1nazartinib 1naporafenib 1milademetan 1lazertinib 1fludarabine phosphate 1fludarabine 1farletuzumab 1enzalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Adenocarcinoma of Lung × farletuzumab × Clear all
NCT01218516 2020-08-20

A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung

Morphotek

Phase 2 Completed
130 enrolled 11 charts
Thoracic

Adenocarcinoma of Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡